# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Expects Gross Proceeds Of Approximately $75M To Fund R&D And General Corporate Purposes
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical com...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $35 price t...
Roth MKM analyst Jason Wittes maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $36 price target.
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...
https://www.marijuanamoment.net/california-legislature-approves-bill-to-break-psychedelics-research-logjam-sending-it-to-governor/